zidovudine

Derm: nail pigmentation

GI: abdominal pain, diarrhea, nausea, anorexia, dyspepsia, HEPATOMEGALY (WITH STEATOSIS), oral mucosa pigmentation, PANCREATITIS, vomiting

Hemat: anemia, neutropenia, pure red-cell aplasia, thrombocytosis

Metab: lipoatrophy

MS: back pain, MYOPATHY

Neuro: headache, weakness, ↓mental acuity, anxiety, confusion, depression, dizziness, insomnia, restlessness, SEIZURES, syncope, tremor

Misc: immune reconstitution syndrome

Interactions ⬆ ⬇

Drug-drug:

↑bone marrow depression with other agents having bone marrow–depressing properties, antineoplastics, radiation therapy, or ganciclovir.
↑risk of neurotoxicity with acyclovir.
Toxicity may be ↑ by concurrent administration of probenecid or fluconazole.
Clarithromycin may ↓ levels and effectiveness.

Availability ⬆ ⬇

(Generic available)

Tablets: 300 mg
Capsules: 100 mg
Oral solution: 50 mg/5 mL
Solution for injection: 10 mg/mL
In combination with: lamivudine (Combivir); abacavir and lamivudine; see Appendix [not included in this PDA edition].

Route/Dosage ⬆ ⬇

HIV

PO (Adults ): 100 mg every 4 hr while awake or 200 mg 3 times daily or 300 mg twice daily (depends on combination and clinical situation).
PO (Children ≥4 wk and ≥30 kg): 300 mg twice daily or 200 mg 3 times daily.
PO (Children ≥4 wk and 9–29.9 kg): 9 mg/kg twice daily or 6 mg/kg 3 times daily.
PO (Children ≥4 wk and 4–8.9 kg): 12 mg/kg twice daily or 8 mg/kg 3 times daily.
IV (Adults and Children >12 yr): 1 mg/kg every 4 hr. Change to oral therapy as soon as possible.
IV (Children ): 120 mg/m² every 6 hr (not to exceed 160 mg/dose) or 20 mg/m²/hr as a continuous infusion.

Prevention of Maternal/Fetal Transmission of HIV Infection

PO (Adults >14 wk Pregnant): 100 mg 5 times daily until onset of labor.
IV (Adults during Labor and Delivery): 2 mg/kg over 1 hr; then continuous infusion of 1 mg/kg/hr until umbilical cord is clamped.
PO (Neonates ): 2 mg/kg every 6 hr until 6 wk of age.
IV (Neonates ): 1.5 mg/kg every 6 hr until 6 wk of age.

US Brand Names ⬆ ⬇

Action ⬆ ⬇

Following intracellular conversion to its active form, inhibits viral RNA synthesis by inhibiting the enzyme DNA polymerase (reverse transcriptase).
Prevents viral replication.

Therapeutic effects:

Virustatic action against selected retroviruses.
Slowed progression and decreased sequelae of HIV infection.
Decreased viral load and improved CD4 cell counts.
Decreased transmission of HIV to infants born to HIV-infected mothers.

Classifications ⬆ ⬇

Therapeutic Classification: antiretrovirals

Pharmacologic Classification: nucleoside reverse transcriptase inhibitors

Pharmacokinetics ⬆ ⬇

Absorption: Well absorbed following oral administration.

Distribution: Widely distributed; enters the CNS.

Metabolism/Excretion: Mostly (75%) metabolized by the liver; 15–20% excreted unchanged by the kidneys.

Half-Life: 1 hr.

Time/Action Profile ⬆ ⬇

(plasma concentrations)

ROUTE	ONSET	PEAK	DURATION
PO	unknown	0.5–1.5 hr	4 hr
IV	rapid	end of infusion	4 hr

Patient/Family Teaching ⬆ ⬇

Explain purpose and side effects of medication. Advise patient to read Patient Information before starting therapy.
Instruct patient to take around the clock, even if sleep is interrupted. Emphasize the importance of compliance with therapy, not taking more than prescribed amount, and not discontinuing without consulting health care provider. Advise patient to take missed dose as soon as remembered unless almost time for next dose; do not double dose.
Zidovudine may cause dizziness or fainting. Caution patient to avoid driving or other activities requiring alertness until response to medication is known.
Inform patient that zidovudine does not cure HIV and may ↓ risk of transmission of HIV to others through sexual contact or blood contamination. Caution patient to use a condom during sexual contact and avoid sharing needles or donating blood to prevent spreading HIV to others.
Instruct patient to notify health care provider promptly if signs of lactic acidosis (feel very weak or tired; feel cold, especially in arms and legs; unusual muscle pain; feel dizzy or light-headed; trouble breathing; fast or irregular heartbeat; stomach pain with nausea and vomiting) or liver problems (yellowing of skin or white part of eyes; loss of appetite; nausea; dark or tea-colored urine; pain, aching, or tenderness on right side of abdomen; light-colored stools) occur.
Instruct patient to notify health care provider promptly if signs of pancreatitis (nausea, vomiting, abdominal pain) or immune reconstitution syndrome (signs and symptoms of an infection or autoimmune disorder) occur.
Instruct patient to notify health care provider promptly if fever, sore throat, signs of infection, muscle weakness, or shortness of breath occurs. Caution patient to avoid crowds and persons with known infections. Instruct patient to use soft toothbrush, to use caution when using toothpicks or dental floss, and to have dental work done prior to therapy or deferred until blood counts return to normal.
Advise patient to notify health care provider of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care provider before taking other medications.
Inform patient that redistribution and accumulation of body fat may occur, causing central obesity, dorsocervical fat enlargement (buffalo hump), peripheral muscle wasting, breast enlargement, and cushingoid appearance.
Rep: Advise women of reproductive potential to notify health care provider if pregnancy is planned or suspected and to avoid breastfeeding. Advise patient taking oral contraceptives to use a nonhormonal method of birth control during therapy. Inform patient of pregnancy exposure registry that monitors outcomes in women exposed to zidovudine during. Enroll patients in the Antiretroviral Pregnancy Registry by calling 1-800-258-4263.
Emphasize importance of regular follow-up exams and blood counts to determine progress and monitor for side effects.

Pronunciation ⬆ ⬇

Code ⬆

NDC Code

31722- Camber Pharmaceuticals, Inc.
- 31722-509- Zidovudine
  - 31722-509-60- 12 BOTTLE in 1 CASE (31722-509-60) / 60 TABLET in 1 BOTTLE

49587- YiChang HEC ChangJiang Pharmaceuical Co.,Ltd.
- 49587-101-
  - 49587-101-01- 25 kg in 1 DRUM (49587-101-01)

49702- ViiV Healthcare Company
- 49702-211- RETROVIR
  - 49702-211-20- 100 CAPSULE in 1 BOTTLE (49702-211-20)

49702- ViiV Healthcare Company
- 49702-212- RETROVIR
  - 49702-212-48- 240 mL in 1 BOTTLE (49702-212-48)

49702- ViiV Healthcare Company
- 49702-213- RETROVIR
  - 49702-213-26- 5 VIAL, SINGLE-USE in 1 CARTON (49702-213-26) / 20 mL in 1 VIAL, SINGLE-USE (49702-213-01)

53104- Cipla Ltd.
- 53104-7545-
  - 53104-7545-1- 30 kg in 1 DRUM (53104-7545-1)

53873- Bora Pharmaceutical Services Inc.
- 53873-070-
  - 53873-070-00- 55000 CAPSULE in 1 DRUM (53873-070-00)

58326- Jiangsu Weiqida Pharmaceutical Co., Ltd.
- 58326-2172-
  58326-2172-1- 25 kg in 1 DRUM (58326-2172-1)

65015- MYLAN LABORATORIES LIMITED
- 65015-703-
  65015-703-61- 100 kg in 1 DRUM (65015-703-61)

65015- Mylan Laboratories Limited
- 65015-765-
  65015-765-61- 100 kg in 1 DRUM (65015-765-61)

65862- Aurobindo Pharma Limited
- 65862-024- Zidovudine
  65862-024-10- 6 BLISTER PACK in 1 CARTON (65862-024-10) / 10 TABLET, FILM COATED in 1 BLISTER PACK

65862- Aurobindo Pharma Limited
- 65862-024-
  - 65862-024-45- 4500 TABLET, FILM COATED in 1 BAG (65862-024-45)

65862- Aurobindo Pharma Limited
- 65862-024- Zidovudine
  65862-024-60- 60 TABLET, FILM COATED in 1 BOTTLE (65862-024-60)

65862- Aurobindo Pharma Limited
- 65862-048- Zidovudine
  - 65862-048-24- 240 mL in 1 BOTTLE (65862-048-24)

65862- Aurobindo Pharma Limited
- 65862-107- Zidovudine
  - 65862-107-01- 100 CAPSULE in 1 BOTTLE (65862-107-01)

65862- Aurobindo Pharma Limited
- 65862-107- Zidovudine
  - 65862-107-10- 10 BLISTER PACK in 1 CARTON (65862-107-10) / 10 CAPSULE in 1 BLISTER PACK

65862- Aurobindo Pharma Limited
- 65862-107-
  - 65862-107-26- 2500 CAPSULE in 1 BAG (65862-107-26)

65862- Aurobindo Pharma Limited
- 65862-258-
  65862-258-37- 50 kg in 1 DRUM (65862-258-37)

65862- Aurobindo Pharma Limited
- 65862-321-
  65862-321-37- 50 kg in 1 DRUM (65862-321-37)

68554- Hetero Labs Limited
- 68554-0017-
  68554-0017-1- 50 kg in 1 DRUM (68554-0017-1)

68554- Hetero Labs Limited
- 68554-0047-
  68554-0047-1- 50 kg in 1 DRUM (68554-0047-1)

70159- Vijayasri Organics Private Limited
- 70159-003-
  70159-003-01- 25 kg in 1 CONTAINER (70159-003-01)

84206- Tianish Laboratories Private Limited
- 84206-0104-
  84206-0104-1- 100 kg in 1 DRUM (84206-0104-1)

section name header

Indications ⬇

Contraind./Precautions ⬆ ⬇

Adv. Reactions/Side Effects ⬆ ⬇